PHATHOM PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 of $0 for the 9-month period ending 2022-09-30, per its 10-Q/A filed 2022-11-09.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 · last filed 2022-11-09
- PHATHOM PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for the quarter ending 2022-09-30 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for the quarter ending 2022-06-30 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for the quarter ending 2022-03-31 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for the quarter ending 2021-12-31 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for fiscal 2021 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for fiscal 2020 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for fiscal 2019 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for fiscal 2018 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q/A · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $0.00 10-Q · filed 2022-08-02 | $0.00 derived: sum of 3 quarters · filed 2022-08-02 | $0.00 derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 | $0.00 derived: sum of 2 quarters · filed 2022-05-10 | $0.00 derived: sum of 3 quarters · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 derived: sum of 3 quarters · filed 2022-11-09 | $0.00 10-K · filed 2022-03-01 |
| 2021-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q/A · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $0.00 10-Q · filed 2022-08-02 | $0.00 derived: sum of 3 quarters · filed 2022-08-02 | $0.00 derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | $0.00 derived: sum of 2 quarters · filed 2022-05-10 | $0.00 derived: sum of 3 quarters · filed 2022-05-10 | $0.00 derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $0.00 10-K · filed 2022-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $0.00 derived: sum of 2 quarters · filed 2020-11-10 | $0.00 10-Q · filed 2020-11-10 | $0.00 derived: sum of 4 quarters · filed 2021-03-30 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2021-03-30 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-12 | $0.00 derived: sum of 2 quarters · filed 2021-03-30 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $0.00 10-K · filed 2021-03-30 | ||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-25 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |